Analyst Research

Report Title Price
Provider: Edison Investment Research
Provider: Reuters Investment Profile
Provider: Edison Investment Research
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Newron Pharmaceuticals SpA's sNN0031 Proves Safety and Efficacy in Phase I/II Study in Parkinson's Disease

Wednesday, 19 Jun 2013 01:02am EDT 

Newron Pharmaceuticals SpA announced that sNN0031 proved safety and initial efficacy in Phase I/II study in Parkinson's disease. In the study, 12 patients with Idiopathic Parkinson's disease (PD) of moderate severity were randomized in a double-blind, placebo-controlled safety, tolerability and preliminary efficacy study. Three increasing doses of sNN0031 (containing human platelet derived growth factor rhPDGF-BB) were delivered by intracerebroventricular administration, using an implantable infusion system. Patients received the drug or placebo for a 2 week period and were followed up to 12 weeks for initial analyses. Safety and tolerability was continuously monitored and efficacy was assessed before and after the 12 weeks using various clinical rating scales and brain imaging (PET-technology). Patients have been followed since 2009. 

Company Quote

-0.15 -0.91%
22 Sep 2014